The CNS Market Outlook to 2008

Executive Summary

The CNS Market Outlook to 2008, provides an essential source of market share data and analysis of the major CNS markets, leading company portfolios and their strategic positioning. This report evaluates the impact of generic competition and late stage pipeline activity to ascertain how the market will develop to 2008, with specific focus on key products and the marketing strength of competing players. The CNS therapy area is becoming a crucial sector for many major pharmaceutical manufacturers. Key players such as Pfizer, GlaxoSmithKline and Merck, now derive large proportions of their revenues from CNS markets, with 2002 delivering strong growth in most areas. Consequently, the years to 2008 are likely to see an increased level of R&D and marketing resources devoted to CNS as manufacturers attempt to maximize revenues from this growing area. Identify potential growth areas within key CNS markets (including Alzheimer’s disease, depression, epilepsy, migraine, multiple sclerosis, pain, Parkinson’s disease and schizophrenia) for your company and develop revenue yielding strategies with this new management report.